ID: hypothesis-h-2a4e4ad2
Hypothesis
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria
Inhibition of alternative mitophagy pathways (BNIP3/NIX) in healthy donor cells prevents degradation of transferable mitochondria while maintaining quality control in recipient neurons.
EvidencePending (0%)📖 8 cit🗣 3 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Inhibition of alternative mitophagy pathways (BNIP3/NIX) in healthy donor cells prevents degradation of transferable mitochondria while maintaining quality control in recipient neurons.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Astrocytes / MSCs"] --> B["Healthy Mitochondria Pool"]
B --> C["BNIP3/NIX-Mediated Mitophagy"]
C --> D["Mitochondria Degraded"]
D --> E["Reduced Donor Pool"]
F["PINK1/Parkin-Independent Mitophagy Bypass"] --> G["Selective BNIP3/NIX Inhibition"]
G --> H["Block Alternative Mitophagy in Donors"]
H --> I["Healthy Mito Accumulate"]
I --> J["Enlarged Transferable Mito Pool"]
J --> K["Tunneling Nanotubes"]
J --> L["Extracellular Vesicles"]
K --> M["Mitochondria Delivery to Neurons"]
L --> M
N["Damaged Neurons"] --> O["Bioenergetic Crisis"]
O --> P["ATP Depletion"]
O --> Q["Excessive ROS"]
M --> R["Healthy Mito Integrate into Neurons"]
R --> S["Restored ATP Production"]
R --> T["Normalized ROS Levels"]
R --> U["Ca2+ Homeostasis Recovery"]
S --> V["Neuronal Rescue"]
T --> V
U --> V
V --> W["Neuroprotection Without Parkin Dependency"]
style A fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style F fill:#264653,stroke:#ffd54f,color:#e0e0e0
style M fill:#1a3a2a,stroke:#81c784,color:#e0e0e0
style W fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Contradicts
BNIP3/NIX inhibition leads to accumulation of dysfunctional mitochondria and increased oxidative stress
Contradicts
Neurodegeneration often involves insufficient rather than excessive mitophagy
Contradicts
Mitochondrial transfer efficiency depends more on recipient cell capacity than donor mitochondrial quantity
📖 Linked Papers (8)Export BibTeX ↗
Harlequin syndrome associated with thoracic epidural anaesthesia.
Anaesthesia reports (2022) · PubMed:35118419 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Transmission dynamics of a linear vanA-plasmid during a nosocomial multiclonal outbreak of vancomycin-resistant enterococci in a non-endemic area, Japan.
Scientific reports (2021) · PubMed:34285270 ↗
8 figures

Figure 1
Minimum inhibitory concentration of vancomycin and teicoplanin for vancomycin-resistant Enterococcus faecium isolates during the outbreak. According to the cr...

Figure 2
Dendrogram of pulsotypes in pulsed-field gel electrophoresis and sequence types in multilocus sequence typing among vancomycin-resistant Enterococcus faecium ...
High resolution spatiotemporal patterns of seawater temperatures across the Belize Mesoamerican Barrier Reef.
Scientific data (2020) · PubMed:33199700 ↗
3 figures

Fig. 1
Map of logger deployment sites in Belize.

Fig. 2
Cross-sectional view of Carrie Bow Caye describing back reef and the two fore reefs in this area: inner fore reef and outer fore reef.
SIRT1 activation by SRT2104 enhances mitophagy and reduces senescence in auditory cells.
Scientific reports (2026) · PubMed:41593189 ↗
No figures
Comprehensive Insights Into Mitophagy: Mechanisms, Disease Associations, and Therapeutic Implications.
Journal of cellular biochemistry (2025) · PubMed:40714832 ↗
No figures
Dimethyl Fumarate Exerts a Neuroprotective Effect by Enhancing Mitophagy via the NRF2/BNIP3/PINK1 Axis in the MPP
Journal of Alzheimer's disease reports (2024) · PubMed:38405353 ↗
No figures
Identification of mitophagy-associated proteins profile as potential plasma biomarkers of idiopathic Parkinson's disease.
CNS neuroscience & therapeutics (2024) · PubMed:37990436 ↗
No figures
Managing risky assets - mitophagy in vivo.
Journal of cell science (2021) · PubMed:34612485 ↗
No figures
📙 Related Wiki Pages (15)
NURR1 Agonist Therapy for Parkinson's DitherapeuticNon-Motor Symptoms Treatment in ParkinsotherapeuticNAD+ Precursors (NMN/NR) for Parkinson'stherapeuticMitochondrial Dynamics Modulators for NetherapeuticNeurorestore Therapies for Parkinson's DtherapeuticMitochondrial TherapeuticstherapeuticMitochondrial Support Strategies for CBStherapeuticNeurturin (NRTN) Therapy for Parkinson'stherapeuticFER GenegeneNSF GenegeneMitochondrial Biogenesis InducerstherapeuticNSF ProteinproteinIcaritin GPER Mitophagy for Parkinson's therapeuticDietary Interventions for Parkinson's DitherapeuticPINK1 Activators for Parkinson's Diseaseterapeutic
🏥 Translation
🧬 3D Protein Structure — BNIP3
No curated PDB or AlphaFold mapping for BNIP3 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for BNIP3/BNIP3L from GTEx v10.
💉 Clinical Trials (4)Relevance: 13%
2
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase I
Highest Phase
Highest Phase
Recruiting·NCT04998357
MSC Transplantation for ALSPhase II
Active·NCT03384433
Planning·NCT05152394
Recruiting·NCT04681943
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BNIP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.0 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.5%
Volatility
Medium
0.0405
Events (7d)
5
Price History
▼24.5%💾 Resource Usage
LLM Tokens
39,356
$0.2361
Total Cost
$0.2361
🔮 Predictions
🔎 Predictions vs Observations5 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention otherwise be ideal candidates for intercellular transfer | otherwise be ideal candidates for intercellular transfer | — no observation — | pending | 0.50 |
| If hypothesis is true, intervention quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging | quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging | — no observation — | pending | 0.50 |
| If hypothesis is true, intervention be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs | be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs | — no observation — | pending | 0.50 |
| If hypothesis is true, intervention be stereotactically injected into the substantia nigra to support dopaminergic neurons | be stereotactically injected into the substantia nigra to support dopaminergic neurons | — no observation — | pending | 0.50 |
| If hypothesis is true, intervention provide mitochondrial support to motor neurons | provide mitochondrial support to motor neurons | — no observation — | pending | 0.50 |
🔮 Falsifiable Predictions (5)
pendingconf 50%
If hypothesis is true, intervention otherwise be ideal candidates for intercellular transfer
Predicted outcome: otherwise be ideal candidates for intercellular transfer
Falsification: Intervention fails to otherwise be ideal candidates for intercellular transfer
pendingconf 50%
If hypothesis is true, intervention quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging
Predicted outcome: quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging
Falsification: Intervention fails to quantify transfer efficiency using mitochondrial-targeted fluorescent proteins and live-cell imaging
pendingconf 50%
If hypothesis is true, intervention be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs
Predicted outcome: be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs
Falsification: Intervention fails to be optimized for different donor cell types, with particular attention to maintaining cell viability and stemness properties in MSCs
pendingconf 50%
If hypothesis is true, intervention be stereotactically injected into the substantia nigra to support dopaminergic neurons
Predicted outcome: be stereotactically injected into the substantia nigra to support dopaminergic neurons
Falsification: Intervention fails to be stereotactically injected into the substantia nigra to support dopaminergic neurons
pendingconf 50%
If hypothesis is true, intervention provide mitochondrial support to motor neurons
Predicted outcome: provide mitochondrial support to motor neurons
Falsification: Intervention fails to provide mitochondrial support to motor neurons
▸Metadata
| status | proposed |
| disease | neurodegeneration |
| target_gene | BNIP3/BNIP3L |
| target_pathway | None |
| _schema_version | 1 |
| composite_score | 0.55 |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
658
Outgoing
147
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.